Patents Assigned to GlaxoSmithKline
  • Meningococcus vaccines
    Patent number: 11707513
    Abstract: Meningococcal vaccines can be improved by including multiple alleles or variants of fHbp, in order to provide broader coverage of the diversity which is known for this protein, and/or by reducing the quantity of an OMV component in each dose.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: July 25, 2023
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Alessia Biolchi, Brunella Brunelli, Marzia Monica Giuliani, Vega Masignani
  • NOVEL USE
    Publication number: 20230220037
    Abstract: The present disclosure relates to an inhibitor of human TRPM3 for use in the treatment or prevention of migraine, including in subjects whose migraines are not responsive to CGRP inhibition or whose migraines are responsive to triptans. Combination therapies are also described. In other aspects, the present disclosure provides methods for identifying suitable patients, methods for identifying inhibitors of human TRPM3, cell lines and agonists for use in such methods and a method for measuring PACAP release.
    Type: Application
    Filed: July 13, 2022
    Publication date: July 13, 2023
    Applicants: GlaxoSmithKline Intellectual Property (No.3) Limited, 23andMe, Inc.
    Inventors: Janet Mary KUMAR, Colin Houston McPHEE, Adam Mohamed NAGUIB, Lea SAROV-BLAT, Claire Yvonne Marie TOWNSEND, Paul Bryan WREN, Clint Ernest YOUNG, Alexander George Steven PRESTON, David Andrew HALL
  • Delivery of RNA to trigger multiple immune pathways
    Patent number: 11696923
    Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: July 11, 2023
    Assignee: GlaxoSmithKline Biologicals, SA
    Inventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
  • C-mannoside compounds useful for the treatment of urinary tract infections
    Patent number: 11697665
    Abstract: Disclosed herein are C-mannoside compounds, compositions thereof and their application as pharmaceuticals for the treatment of human disease. Methods of inhibition of FimH activity in a human subject are also provided for the treatment of diseases such as bacterial infection, Crohn's disease (CD) and Inflammatory Bowel Disease (IBD).
    Type: Grant
    Filed: July 9, 2021
    Date of Patent: July 11, 2023
    Assignees: Fimbrion Therapeutics, Inc., GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Michael Joseph Bishop, Eugene L. Stewart, Katherine Louisa Widdowson, James Walter Janetka, Laurel Kathryn McGrane
  • Delivery of RNA to trigger multiple immune pathways
    Patent number: 11690865
    Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: July 4, 2023
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
  • Delivery of RNA to trigger multiple immune pathways
    Patent number: 11690862
    Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: July 4, 2023
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
  • Delivery of RNA to trigger multiple immune pathways
    Patent number: 11690864
    Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: July 4, 2023
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
  • Delivery of RNA to trigger multiple immune pathways
    Patent number: 11690863
    Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: July 4, 2023
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
  • Delivery of RNA to trigger multiple immune pathways
    Patent number: 11690861
    Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: July 4, 2023
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
  • CHIMERIC ANTIGEN RECEPTORS TARGETING CLAUDIN-3 AND METHODS FOR TREATING CANCER
    Publication number: 20230192842
    Abstract: Chimeric antigen receptors (CARs) which include an antigen binding protein that binds to a discontinuous epitope on human claudin-3 comprising at least N38 and E153 of SEQ ID NO:13 are described. Also described herein includes polynucleotides encoding the antigen binding protein, the CARs, immune effector cells containing the CARs, pharmaceutical compositions containing the immune effector cells, and methods of treating cancer with the immune effector cells.
    Type: Application
    Filed: September 22, 2022
    Publication date: June 22, 2023
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventor: Thomas Southgate
  • Methods and apparatus for variable emulsification
    Patent number: 11666874
    Abstract: The invention comprises a novel modular, generalizable meso-micro-nano-fluidic platform apparatus, design and methodology which in exemplary embodiments may be applied in conjunction with a novel external triggering and automation/feedback loop control mechanism deployed via computer to explore the phase space of single or double emulsification for applications including the encapsulation of hydrophilic active pharmacological ingredients (APIs). End use applications include the mass production of particulate encapsulation of hydrophobic or hydrophilic APIs with automatic or user-supervised feedback methodology to control and discover mass production or per-drug customized settings of interest for the manufacture of novel or extant therapeutics.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: June 6, 2023
    Assignees: Glaxosmithkline Intellectual Property Deveelopment Limited, Massachusetts Institute of Technology
    Inventors: David Lai, Filippos Touriomousis, Andreas Mershin, Neil Gershenfeld
  • Methods of administering lipid formulations with viral immunogens
    Patent number: 11666534
    Abstract: RNA encoding an immunogen is delivered in a liposome for the purposes of immunisation. The liposome includes lipids which have a pKa in the range of 5.0 to 7.6 and, preferably, a tertiary amine. These liposomes can have essentially neutral surface charge at physiological pH and are effective for immunisation.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: June 6, 2023
    Assignee: GlaxoSmithKline Biologicals SA
    Inventor: Andrew Geall
  • Immunisation of large mammals with low doses of RNA
    Patent number: 11655475
    Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 ?g and 100 ?g. Thus, the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 ?g and 100 ?g of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: May 23, 2023
    Assignee: GlaxoSmithKline Biologicals SA
    Inventor: Andrew Geall
  • Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof
    Patent number: 11649217
    Abstract: The present disclosure relates to crystalline form CS1 and CS9 of a hypoxia-inducible factor prolyl hydroxylase inhibitor compound (I) GSK1278863, processes for preparation, and uses for preparing drugs treating and/or preventing anemia thereof.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: May 16, 2023
    Assignee: GlaxoSmithKline Intellectual Property (NO.2) Limited
    Inventors: Minhua Chen, Yanfeng Zhang, Jinqiu Wang, Xiaoyu Zhang
  • Anti-ICOS and anti-PD-1 antibody combination therapy
    Patent number: 11649289
    Abstract: The present invention provides methods for increasing expression of ICOS on an effector T cell comprising contacting said effector T cell with an anti-PD-1 antibody. The present invention also provides methods for decreasing expression of ICOS on a regulatory T cell comprising contacting said regulatory T cell with an anti-PD-1 antibody. The present invention provides methods for increasing sensitivity to an agent directed to ICOS in a human comprising administering to the human an anti-PD1 antibody. The present invention also provides methods of treating cancer in a human in need thereof comprising administering an anti-PD-1 antibody and an anti-ICOS antibody to said human, wherein the anti-PD-1 antibody increases T cell sensitivity to the ICOS antibody.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: May 16, 2023
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Sabyasachi Bhattacharya, Paul M. Bojczuk, Heather L. Jackson, Mili Mandal, Hong Shi, Sapna Yadavilli, Niranjan Yanamandra
  • Prolyl hydroxylase inhibitors
    Patent number: 11643397
    Abstract: The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
    Type: Grant
    Filed: July 23, 2021
    Date of Patent: May 9, 2023
    Assignee: GlaxoSmithKline LLC
    Inventors: Kevin J. Duffy, Duke M. Fitch, Jian Jin, Ronggang Liu, Antony N. Shaw, Kenneth Wiggall
  • Indanes as NRF2 activators
    Patent number: 11643407
    Abstract: The present invention relates to indane compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: May 9, 2023
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventor: Jeffrey K. Kerns
  • Vaccine for eliciting immune response comprising lipid formulations and RNA encoding multiple immunogens
    Patent number: 11638694
    Abstract: Provided are vaccines for eliciting an immune response. The vaccines for eliciting an immune response comprise RNA encoding an immunogen, which is delivered in a liposome for the purposes of immunisation. The liposome includes lipids which have a pKa in the range of 5.0 to 7.6 and, preferably, a tertiary amine. These liposomes can have essentially neutral surface charge at physiological pH and are effective for immunisation.
    Type: Grant
    Filed: June 23, 2022
    Date of Patent: May 2, 2023
    Assignee: GlaxoSmithKline Biologicals SA
    Inventor: Andrew Geall
  • Vaccine for eliciting immune response comprising RNA encoding an immunogen and lipid formulations comprising mole percentage of lipids
    Patent number: 11638693
    Abstract: Provided are vaccines for eliciting an immune response. The vaccines for eliciting an immune response comprise RNA encoding an immunogen, which is delivered in a liposome for the purposes of immunisation. The liposome includes lipids which have a pKa in the range of 5.0 to 7.6 and, preferably, a tertiary amine. These liposomes can have essentially neutral surface charge at physiological pH and are effective for immunisation.
    Type: Grant
    Filed: June 23, 2022
    Date of Patent: May 2, 2023
    Assignee: GlaxoSmithKline Biologicals SA
    Inventor: Andrew Geall
  • SUBSTITUTED PYRIDINES AS DNMT1 INHIBITORS
    Publication number: 20230101987
    Abstract: The invention relates to substituted pyridine derivatives that are inhibitors of the activity of DNA methyltransferase 1 (DNMT1). The invention also relates to pharmaceutical compositions comprising such compounds and methods of using such compounds in the treatment of cancer, pre-cancerous syndromes, beta haemoglobinopathy disorders, and other diseases associated with inappropriate DNMT1 activity.
    Type: Application
    Filed: October 14, 2022
    Publication date: March 30, 2023
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Andrew B. BENOWITZ, David T. Fosbenner, Bryan Wayne King, Stuart Paul Romeril